Track Inhibikase Therapeutics (IKT) shelf registrations, ATM offerings, warrant and convertible activity, and Nasdaq listing compliance, sourced from SEC filings. The cash position and Nasdaq compliance below are free; the full IKT offering history and dilution risk rating are part of AskEdgar Pro.
Pending and completed IKT offerings, shelf registrations with remaining raisable capacity, at-the-market programs and equity lines, extracted from SEC filings.
Outstanding IKT warrants and convertible notes with exercise and conversion prices, remaining amounts and price-protection terms.
IKT reverse split status, past split ratios, former ticker symbols and lock-up expirations.
Rights attached to past IKT financings and who holds the stock: right of first refusal, participation and registration rights, share issuance restrictions, ownership and legal counsel.
An AI summary of management's commentary on IKT liquidity, going-concern risk and funding plans, plus analyst insights.